ULTA:NASDAQUlta Beauty, Inc. Analysis
Data as of 2026-08-29 - not real-time
$517.50
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
At $517.50, Ulta Beauty, Inc. shows no decisive moving-average alignment, leaving the trend neutral. The last 30 days have gained 7.9%. RSI sits at 49.3, which reads as neutral, and MACD momentum is bearish. Watch $493.11 as support and $566.73 as the nearer resistance level.
Valuation screens as fair, on a P/E of 18.9 with no clean sector comparison available. The average analyst target implies 20.5% above today's level. Revenue is growing at 8.9% on a 9.3% profit margin.
Risk comes out at 5 of a possible 10, a moderate reading. With 30-day volatility of 38.8%, a beta of 0.47 and a maximum drawdown of 36.2%, position sizing matters here. The wider market backdrop reads extreme greed at 96 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 3 out of 10.
Valuation screens as fair, on a P/E of 18.9 with no clean sector comparison available. The average analyst target implies 20.5% above today's level. Revenue is growing at 8.9% on a 9.3% profit margin.
Risk comes out at 5 of a possible 10, a moderate reading. With 30-day volatility of 38.8%, a beta of 0.47 and a maximum drawdown of 36.2%, position sizing matters here. The wider market backdrop reads extreme greed at 96 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 3 out of 10.
Top Market Events
Ulta Beauty’s fiscal Q2 2026 net sales increased 8.Ulta Beauty posted a clean earnings beat and raised its full year outlook, yet traders punished the stock in heavy...Investing.com -- Ulta Beauty Inc NASDAQ:ULTA posted second-quarter results that exceeded analyst expectations, with...
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 3/10
Key Factors
- Trading below the 200-day average of 555.67
- MACD momentum is negative
- 30-day price change of +7.9%
Medium Term
1–3 yearsNeutral
Model confidence: 2/10
Key Factors
- Trading below the 200-day average of 555.67
- Analyst targets imply +20.5% versus the current price
- MACD momentum is negative
Long Term
> 3 yearsNeutral
Model confidence: 3/10
Key Factors
- Analyst targets imply +20.5% versus the current price
- P/E ratio of 18.9
- Return on equity of 46.1%
Key Metrics & Analysis
Financial Health
Revenue Growth8.90%
Profit Margin9.34%
P/E Ratio18.9
ROE46.12%
ROA14.84%
Debt/Equity95.47
P/B Ratio8.2
Op. Cash Flow$1.6B
Free Cash Flow$918.4M
Technical Analysis
TrendNeutral
RSI49.3
Support$493.11
Resistance$566.73
MA 20$531.06
MA 50$497.45
MA 200$555.67
MACDBearish
VolumeIncreasing
Fear & Greed Index95.66
Valuation
Fair Value$347.53
Target Price$623.54
Upside/Downside20.49%
GradeFair
TypeGrowth
Risk Assessment
Beta0.47
Volatility38.75%
Sector RiskHigh
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.